|
Video: What is a Stock Split?
|
|
Innate Pharma is a global, clinical-stage, oncology-focused biotech company focused on improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Co.'s product pipelines include: Lacutamab, which is for the treatment of certain subtypes of T-cell lymphoma; Monalizumab, which is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells; Avdoralimab, which is a monoclonal antibody blocking C5a binding to C5aR1; and IPH5301, which is a potential anticancer therapy for patients with advanced or metastatic disease in selected solid tumors. According to our Innate Pharma SA stock split history records, Innate Pharma SA has had 0 splits. | |
|
Innate Pharma SA (IPHA) has 0 splits in our Innate Pharma SA stock split history database.
Looking at the Innate Pharma SA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Innate Pharma SA shares, starting with a $10,000 purchase of IPHA, presented on a split-history-adjusted basis factoring in the complete Innate Pharma SA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/18/2019 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$6.14 |
|
End price/share: |
$2.38 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-61.24% |
|
Average Annual Total Return: |
-19.21% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,875.36 |
|
Years: |
4.44 |
|
|
|
|
|